Robert W. Baird Lowers Diplomat Pharmacy (DPLO) to Underperform

Robert W. Baird downgraded shares of Diplomat Pharmacy (NYSE:DPLO) from a neutral rating to an underperform rating in a report released on Wednesday morning, MarketBeat reports. The brokerage currently has $10.00 price objective on the stock, down from their prior price objective of $22.00.

Several other equities research analysts also recently commented on DPLO. ValuEngine downgraded shares of Diplomat Pharmacy from a hold rating to a sell rating in a report on Tuesday. Zacks Investment Research downgraded shares of Diplomat Pharmacy from a hold rating to a sell rating in a report on Tuesday, October 23rd. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $24.50.

NYSE DPLO traded up $0.04 during trading on Wednesday, hitting $16.09. 1,694,581 shares of the company’s stock traded hands, compared to its average volume of 1,097,092. The company has a market cap of $1.10 billion, a PE ratio of 19.15 and a beta of 0.95. Diplomat Pharmacy has a 12-month low of $13.31 and a 12-month high of $28.74. The company has a quick ratio of 0.63, a current ratio of 0.95 and a debt-to-equity ratio of 0.58.

Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings data on Tuesday, November 6th. The company reported $0.01 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by ($0.21). The business had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.42 billion. Diplomat Pharmacy had a net margin of 0.04% and a return on equity of 5.31%. Diplomat Pharmacy’s revenue for the quarter was up 22.0% compared to the same quarter last year. During the same period last year, the company earned $0.01 earnings per share. As a group, equities research analysts anticipate that Diplomat Pharmacy will post 0.81 EPS for the current year.

In other news, Director Philip R. Hagerman sold 209,367 shares of the stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $19.07, for a total value of $3,992,628.69. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Philip R. Hagerman sold 57,500 shares of the stock in a transaction dated Tuesday, September 11th. The stock was sold at an average price of $19.21, for a total transaction of $1,104,575.00. The disclosure for this sale can be found here. Corporate insiders own 24.70% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Public Employees Retirement Association of Colorado increased its position in shares of Diplomat Pharmacy by 142.2% in the third quarter. Public Employees Retirement Association of Colorado now owns 6,307 shares of the company’s stock worth $122,000 after purchasing an additional 3,703 shares during the last quarter. Cornerstone Wealth Management LLC bought a new position in shares of Diplomat Pharmacy in the third quarter worth approximately $340,000. United Services Automobile Association bought a new position in shares of Diplomat Pharmacy in the second quarter worth approximately $210,000. D.A. Davidson & CO. bought a new position in shares of Diplomat Pharmacy in the second quarter worth approximately $215,000. Finally, UBS Group AG increased its position in shares of Diplomat Pharmacy by 186.4% in the first quarter. UBS Group AG now owns 8,491 shares of the company’s stock worth $171,000 after purchasing an additional 5,526 shares during the last quarter. 82.05% of the stock is currently owned by hedge funds and other institutional investors.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Featured Story: Fundamental Analysis

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit